Glancy Binkow & Goldberg LLP Announces Investigation on Behalf of Shareholders of Chemed Corporation

Before you go, we thought you'd like these...
Before you go close icon

Glancy Binkow & Goldberg LLP Announces Investigation on Behalf of Shareholders of Chemed Corporation

LOS ANGELES--(BUSINESS WIRE)-- Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of shareholders of Chemed Corporation ("Chemed" or the "Company") (NYS: CHE) concerning possible breaches of fiduciary duties by the Company or its fiduciaries. Chemed, through its subsidiaries, operates in the healthcare and repair and maintenance fields in the United States. The Company's Vitas segment offers hospice and palliative patient-care services through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Please contact us at (212) 682-5340, toll-free at (888) 773-9224, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.


The investigation is related to allegations that Chemed billed Medicare for unnecessary and fraudulent treatments - including billing for hospice care for patients who were not terminally ill - and whether the Company's board of directors breached their fiduciary duties or allowed Chemed to engage in potential violations of the federal False Claims Act. In May 2013, the United States Department of Justice filed a lawsuit under the False Claims Act against Chemed and its affiliates, alleging that the Company systematically defrauded Medicare.

If you purchased Chemed shares and still hold those shares, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.



Glancy Binkow & Goldberg LLP
Los Angeles, CA
Michael Goldberg, 888-773-9224
or
New York, NY
Gregory Linkh, 212-682-5340 or 888-773-9224
or
shareholders@glancylaw.com
www.glancylaw.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Glancy Binkow & Goldberg LLP Announces Investigation on Behalf of Shareholders of Chemed Corporation originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners